Back HIV/HBV Coinfection

HIV/HBV Coinfection

Tenofovir Usually Suppresses Hepatitis B in HIV/HBV Coinfected People

Tenofovir led to undetectable hepatitis B virus (HBV) levels in 87% of HIV positive coinfected individuals, and a similar proportion maintained viral suppression over 6 years, according to a study described in the June 20 advance edition of Hepatology.

alt

Read more:

ASCO: HCV Reactivation, Brain Involvement Do Not Worsen Lymphoma Survival for People with HIV

Reactivation of hepatitis C was common among HIV positive people with lymphoma, but did not appear to lead to worse outcomes or decreased survival, according to a study presented at the 50th American Society of Clinical Oncology (ASCO) meeting this week in Chicago. A related study found that having central nervous system involvement at the time of diagnosis did not decrease survival of people with AIDS-related lymphoma.

alt

Read more:

Coverage of the 2014 Conference on Retroviruses and Opportunistic Infections

HIVandHepatitis.com coverage of the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014), March 3-6, 2014, in Boston.

Conference highlights include new treatments for hepatitis C, HIV experimental therapies and treatment strategies, HIV cure research, HIV-related conditions, treatment as prevention and PrEP, and HIV/HCV coinfection.

Full listing by topic

Selected presentations and slide webcasts 

3/9/14

alt

CROI 2014 & EASL 2014: Treating Hepatitis B and C in HIV+ People Reduces Liver Disease

Effective antiviral treatment that suppresses hepatitis B virus (HBV) repliaction or eradicates hepatitis C virus (HCV) can lower the risk of developing advanced liver disease including cirrhosis, hepatocellular carcinoma, and decompensation in people with HIV and viral hepatitis coinfection, according to studies presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI) and EASL International Liver Congress.

alt

Read more:

Coverage of the 2014 Conference on Retroviruses and Opportunistic Infections

HIVandHepatitis.com coverage of the 21st Conference on Retroviruses and Opportunistic infections (CROI 2014), March 3-6, 2014, in Boston.

Conference highlights include new treatments for hepatitis C, HIV experimental therapies and treatment strategies, HIV cure research, HIV-related conditions, treatment as prevention and PrEP, and HIV/HCV coinfection.

Full HIVandHepatitis.com coverage by topic

Selected presentations and slide webcasts 

3/9/14

alt